Cardiac Biotech Solutions Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Charles K. Martin
- Full Time Employees
- 4
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 340 State Place Las Vegas NV United States of America 92029
- IPO Date
- Feb 16, 2016
- CIK
- 0001022183
- Website
- cardiacbiotech.com
- Similar Companies
- Business
- Cardiac Biotech Solutions Inc. (OTC: CBSC) provides innovative products and services in the ambulatory non-invasive cardiac monitoring space through its international subsidiaries; core offerings include FDA-cleared and CE-marked electrocardiogram (EKG) devices such as the MyCardia AT cardiac event monitor, interactive cloud-based acquisition software powered by AWS connectivity, and smartphone applications for iOS, Android, and WeChat platforms that enhance patient compliance and deliver accurate data to physicians for diagnosing abnormal heart rhythms. The company, founded in 1987 and headquartered at 10845 Griffith Peak Drive, Suite 200, Las Vegas, Nevada, with additional offices in Tampa, Florida, and Washington, D.C., targets healthcare providers and patients at risk of cardiac conditions across the United States, Central America, Southeast Asia, Canada, and other international markets, focusing on shifting care from inpatient to outpatient settings. In May 2025, the company changed its name from CB Scientific Inc. to Cardiac Biotech Solutions Inc.; recent developments include securing a Health Canada license for the MyCardia AT (branded CardioHolter AT) in September 2025, signing an exclusive five-year distribution agreement with Noventis Medical for Costa Rica, Panama, Colombia, and Argentina, and receiving a $375,000 purchase order from the partner for 2,500 MyCardia AT devices alongside launch of a recurring revenue rental program for devices, software, and apps.
Contrasting ADMA Biologics (NASDAQ:ADMA) and Cardiac Biotech Solutions (OTCMKTS:CBSC)
Cardiac Biotech Solutions, Inc. Secures Health Canada License for MyCardia AT Device, Now Branded as CardioHolter AT
CBSC Announces $375,000 Purchase Order and Launch of Recurring Revenue Program with Noventis Medical
Cardiac Biotech Solutions, Inc. (CBSC) Signs Exclusive 5-Year Distribution Agreement with Noventis Medical Covering Costa Rica, Panama, Colombia, and Argentina
CB Scientific, Inc. (CBSC) Announces Corporate Name Change to Cardiac Biotech Solutions, Inc.
CB Scientific Inc. (CBSC) Formally Launches Next Generation MyCardia AT Cardiac Monitor
CB Scientific, Inc. Appoints Trip Thomas as Chief Financial Officer
CB Scientific, Inc. Announces Voluntary Delisting from OTCQB Venture Market
CB Scientific, Inc. Concludes its Annual Meeting of Stockholders
CB Scientific, Inc. 2023 Year in Review
CB Scientific, Inc. (CBSC) Announces the Engagement of MaloneBailey, LLP
CB Scientific, Inc. (CBSC) Announces the Launch of Direct-to-Consumer Heart Wellness Check-Up Program in Bangkok, Thailand
CB Scientific, Inc. (CBSC) enters into a Consultant Services Agreement with the Dorchester Group LLC
CB Scientific, Inc. (CBSC) Distributor Mango Wellness Comes to an Agreement to Provide Services to Three Major Hospital Chains in Thailand
CB Scientific, Inc. Announces Appointment of New Director for Asia Pacific